Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00519 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Muge Didem Orhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience, Graduate School of Education, Bahçeşehir University, Istanbul 34353, Turkey. Hauptthemen laut MEDLINE: Piperidines, Interleukin-17, Indazoles, Remyelination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Arastirma Kurumu, Bahçesehir Üniversitesi.
Abstract (Originalsprache)
IL-17A is a pro-inflammatory cytokine that significantly contributes to the pathogenesis of autoimmune diseases, including multiple sclerosis (MS). Previous studies have suggested that PARP-1 inhibitors can modulate IL-17A-mediated inflammation, prompting the investigation of Niraparib, an FDA-approved PARP-1 inhibitor, as a potential therapeutic agent for MS. In this study, we hypothesized that Niraparib could disrupt the interaction between IL-17A and its receptor, IL-17RA. To evaluate this, we employed a binary quantitative structure-activity relationship (QSAR) model against anti-inflammatory diseases, which indicated Niraparib's potential efficacy against MS. In silico analyses were conducted to identify key interaction sites and critical amino acid residues involved in the IL-17A/IL-17RA binding. Molecular docking simulations demonstrated Niraparib's capability to interfere with these interactions. It has demonstrated significant efficacy in inhibiting the interaction between the IL-17A ligand and its receptor via reporter assay. In vivo assessments were performed using a cuprizone-induced demyelination model. Immune profiling revealed modulation of various T cell subsets and B cells, while cytokine analysis indicated a shift in inflammatory responses. Histological evaluations confirmed reduced demyelination and enhanced remyelination in affected brain regions. These findings support Niraparib's potential as a therapeutic option for MS, warranting further exploration of its mechanisms and clinical relevance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience, Graduate School of Education, Bahçeşehir University, Istanbul 34353, Turkey.
- Department of Medical Biology, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
- Neurooncology Laboratory, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
- Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, Faculty of Medicine, Bahçeşehir University, Istanbul 34353, Turkey.
- Lab for Innovative Drugs (Lab4IND), Computational Drug Design Center (HITMER), Bahçeşehir University, Istanbul 34353, Turkey.
- Neuroscience Program, University of Bonn, Bonn 53113, Germany.
ORCID-Profile: Huseyin Tunc, Timucin Avsar
Förderung
- Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
- Bahçesehir Üniversitesi
Zitieren
APA
Orhan, M. D., Oktay, L., Cınar, A. I., Yesil, A. K., Tunc, H., Eren, F., Durdagi, S., & Avsar, T. (2025). Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00519
Vancouver
Orhan MD, Oktay L, Cınar AI, Yesil AK, Tunc H, Eren F, et al. Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00519
BibTeX
@article{Orhan2025,
author = {Orhan, Muge Didem and Oktay, Lalehan and Cınar, Ayşe Irem and Yesil, Aybek Kagan and Tunc, Huseyin and Eren, Fatih and Durdagi, Serdar and Avsar, Timucin},
title = {Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00519}
}
EUVIMED